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Abstract
Aspartylglucosaminuria (AGU), a recessively inherited lysosomal storage disease, is the most common disorder of
glycoprotein degradation with a high prevalence in the Finnish population. It is a lifelong condition affecting on
the patient’s appearance, cognition, adaptive skills, physical growth, personality, body structure, and health. An
infantile growth spurt and development of macrocephalia associated to hernias and respiratory infections are the
key signs to an early identification of AGU. Progressive intellectual and physical disability is the main symptom
leading to death usually before the age of 50 years.
The disease is caused by the deficient activity of the lysosomal enzyme glycosylasparaginase (aspartylglucosaminidase,
AGA), which leads to a disorder in the degradation of glycoasparagines – aspartylglucosamine or other glycoconjugates
with an aspartylglucosamine moiety at their reducing end – and accumulation of these undegraded glycoasparagines in
tissues and body fluids. A single nucleotide change in the AGA gene resulting in a cysteine to serine substitution (C163S)
in the AGA enzyme protein causes the deficiency of the glycosylasparaginase activity in the Finnish population.
Homozygosity for the single nucleotide change causing the C163S mutation is responsible for 98% of the AGU cases in
Finland simplifying the carrier detection and prenatal diagnosis of the disorder in the Finnish population. A mouse strain,
which completely lacks the Aga activity has been generated through targeted disruption of the Aga gene in embryonic
stem cells. These Aga-deficient mice share most of the clinical, histopathologic and biochemical characteristics of human
AGU disease. Treatment of AGU mice with recombinant AGA resulted in rapid correction of the pathophysiologic
characteristics of AGU in non-neuronal tissues of the animals. The accumulation of aspartylglucosamine was reduced by
up to 40% in the brain tissue of the animals depending on the age of the animals and the therapeutic protocol. Enzyme
replacement trials on human AGU patients have not been reported so far. Allogenic stem cell transplantation has not
proved effective in curing AGU.
Keywords: Aspartylglucosaminuria, Aspartylglycosaminuria, Lysosome, Lysosomal strorage, Aspartylglucosamine,
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Background
Aspartylglykosaminuria (AGU) has been found to be the
most common recessively inherited disease in the
Finnish population. It has been described in early 1960’s
and so far approximately 260 Finnish patients and single
patients representing all races and several nationalities
have been identified with this genetic defect. The clin-
ical, molecular genetic and biochemical research data is
reviewed in this paper for this often poorly recognized
but still rather commonly occurring disability. Practical
implications of the available knowledge onto everyday










Aspartyglycosaminuria (AGU) was first described in 1968
in a British family with two seriously intellectually disabled
children, who excreted large amounts of aspartylglucosa-
mine (2-acetamido-1-(β’-L-aspartamido)-1,2-didieoxyglu-
cose; GlcNAc-Asn) in their urine [1]. At the same time in
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Finland, a screening study concerning amino acids in urine
among 2177 intellectually disabled individuals identified 11
patients with similar clinical symptoms and excretion of
large amounts of an unknown compound containing aspar-
tic acid in their urine [2]. The combined evidence from the
Finnish and British patients demonstrated that all of them
suffered from AGU. Eventually this led to the realization
that enrichment of AGU had occurred in the Finnish
population.
AGU is the most common lysosomal storage disease
caused by a disorder in degradation of glycoproteins. Glyco-
proteins commonly contain carbohydrate moieties, which
are joined to protein moiety by means of an N-glycosidic
bond between amino acid L-asparagine and monosacchar-
ide N-acetylglucosamine. AGU is caused by deficient activ-
ity of the lysosomal enzyme glycosylasparaginase that
cleaves the N-glycosidic bond between the L-asparagine
and N-acetylglucosamine moieties of GlcNAc-Asn. This
enzyme deficiency results in the accumulation of unde-
graded aspartylglucosamine and a series of other glycoas-
paragines i.e., glycoconjugates containing an L-asparagine
moiety linked to the carbohydrate chain in tissues and body
fluids of the affected [3, 4].
Population genetics
AGU belongs to the group of disorders referred to as the
Finnish disease heritage [3–6]. Approximately 260 patients
have been reported in Finland (2014 population: 5.3 mil-
lion), and 160 of those are currently alive. Approximately
200–300 living AGU patients are currently known world-
wide. Approximately 30 patients are known to be living in
Sweden and Norway, and at least some of them are de-
scendants of Finns [7]. AGU frequency of 1 in 3643 was
found in a study of children in eastern Finland corre-
sponding to a carrier rate of 1 in 30 in that population [8].
In about 98% of the Finnish AGU patients, the disease is
caused by a single point mutation in the glycosylasparagi-
nase gene (see later). It is estimated that the carrier of this
mutation is 1 in 50–60 among Finns [9, 10]. Annually, 1–
3 children with AGU are born in Finland implying a
prevalence of 1.7–5/100.000 live births in its population.
Single, but increasing number of AGU patients have been
reported globally and in all races suggesting that the dis-
ease may be underdiagnosed. In many of these patients
the disease-causing gene mutation is different from that of
common in the Finnish population (see later).
Clinical description
AGU is a neuropsychiatric, generalized disease with a pro-
gressive course affecting the whole body and resulting in
premature aging. A detailed clinical picture according to
the age covering the patients’ cognition, speech, self-help,
motor skills, personality, growth, mouth, head and face,
skin, connective tissue, state of health, as well as laboratory
and X-ray findings is given in Tables 1 and 2 [11–13]. The
speed of progression of AGU varies between separate pa-
tients being a little slower among females.
At birth, the children with AGU are usually healthy
with normal birth measurements. An infantile growth
spurt (Fig. 1) and increased head circumference (Fig. 2)
are the first symptoms [14] associated to hernias and re-
spiratory infections are the key signs to an early identifi-
cation of AGU. In childhood AGU appears as delayed
speech development, poor motor coordination and ex-
ceptional placidity or periods of hyperactivity [15]. On
the average, the clinical diagnosis of AGU is made at the
age of 5 years. The developmental profile comprises
three phases: i) Firstly, an abnormally slow but positive
development up to the age of 13–16 years, ii) a stable
period with a mild and slow decline up to the age of 25–
28 years, and finally iii) a rapid decline after the age of
30 years. In psychological tests, the under school-aged
AGU children score at a subnormal intellectual disability
level, school-aged children at a mild intellectual disabil-
ity level, teenagers and young adults at a moderate level,
adults at a severe level, and the middle aged at a pro-
found intellectual disability level [16, 17]. The patient’s
appearance, facial features and body shape as well as
their personality are characteristic to the disease (Fig. 3
a-b) [18]. The oral health is impaired in almost all adult
patients. Every third patient suffers from epileptic sei-
zures (often nocturnal frontal lobe epilepsy), every fifth
from psychiatric disorders and every 20th from rheuma-
toid arthritis as an associated condition [19–23]. There
are many laboratory and imaging findings characteristic
to AGU, which are of no clinical significance. It is useful
to be aware of these so that the patient is not referred
for further examination, for example bone marrow aspir-
ation due to a low white blood cell count in their periph-
eral blood. Ribs are thick and misshapen, while long
bones are thin. The vertebra may show skeletal abnor-
malities. The skull is often thick and as the patient ages,
the loss of brain cells is evident. The disease has a char-
acteristic MRI finding [24]. A special phenomenon is the
reduction or shrinking of head circumference as the pa-
tient ages (Fig. 2) [25].
Molecular genetics
The primary defect in AGU is a mutation in the AGA gene
comprising 9 exons and located on 4q34.3. The AGA se-
quence is highly conserved in evolutionary terms [26].
In the Finnish patients with AGU Mononen et al. [27],
Fisher and Aronson [28] and Ikonen et al. [29] independ-
ently identified homozygosity for two point mutations
(G482A and G488C) in the cDNA of glycosylasparaginase.
The first nucleotide change results in the replacement of
arginine by glutamine (R161Q) and the second change re-
sults in a cysteine-to-serine substitution (C163S) in the
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Growth Cognition Personality Speech Self-help Motor skills
<2 Early growth spurt +1-
+2sd
Normal “An easy baby” Normal Normal Stiffness in hips
2–5 +1SD Subnormal Well-behaved and
fussy
Delayed Delayed Walks clumsily
6–9 0- + 1sd Mild ID Talkative, kind,
stubborn
Unclear Delayed Can bike and ski, not
skate














Tends to withdraw “Soft” Able to do little
shopping
No change
20–24 Girls gain weight Severe ID Attached to parents,
shows no interest
to opposite sex
“Soft” Able to move outdoors
in familiar surroundings
No more biking nor
skiing




May walk without a
goal
35–44 No change Severe ID Confused Few words Constant need of help Legs seem not to
respond
45+ Loss of weight Profound ID Sits still for hours,
angry when
disturbed
No speech Constant need of help Poor balance/wheel
chair



















Vacuolated cells in all tissues















decreased T2 signal intensity
of the thalami
6–9 Gingivitis, oral candida No change No change Bulging
abdomen,
knock-knees
Benign subcutaneous tumors Thick and misshapen ribs,
vertebral dysplasia
10–15 Gingival overgrowts No change Facial seborrhoea Broad and low
ball of foot
Arthritis rheumatoides Decreased T2 pulvinar signal
intensity, mild cerebral
atrophy
16–19 Edemic cheeks, cross
bite
No change Angiokeratoma Thoracic
deformity
Psychotic periods, epilepsy Neutropenia, thrombopenia,
mild cerebellar atrophy










25–34 No change Thick
eyebrows
Facial rosacea Poor carriage Epilepsy –




Loose skin Muscle atrophy
and hypotony
Bursitis, osteoporosis, orofacial Attenuation in EEG






Abscesses, fistula of skin,
diarrhoea, anaemia, hearth
insufficiency, p
Progression of cerebral and
cerebellar atrophy
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glycosylasparaginase enzyme protein. Site-directed muta-
genesis and expression studies in COS cells demonstrated
that only the cysteine to serine substitution (C163S)
causes the deficiency of glycosylasparaginase activity [30].
The mutation destroys a disulfide bond [31] and leads to
conformational changes in the inactive prercursor enzyme
protein preventing its autocleavage into subunits and an
active enzyme protein [32].
Screening of 115 Finnish AGU patients demonstrated
that 98% of them were homozygous carrying the same
two nucleotide changes (G482A and G488C) [33]. Thus,
this so called AGUFIN major mutation is a result of a
founder effect and demonstrates a high molecular
homogeneity in the AGU alleles in the Finnish popula-
tion. A genealogical study among nine AGU patients
from seven families living in northern Norway, who were
homozygous for the AGUFIN major mutation, proved
Finnish ancestry in all pedigrees. These Finnish immi-
grants originated from northern Finland in a continuous
immigration movement from 1700 to 1900. The second
AGU causing allele in the Finnish patients is a 2 base
pair deletion in exon 2 of the gene (AGUFIN minor
Fig. 1 A growth curve of a female AGU patient demonstrates excessive infantile growth, early but weak pubertal growth spurt, and reduced adult height
Fig. 2 Comparison of head circumferences (SD) of 78 AGU patients
and Finnish normative data according chronological age shows
macrocephaly in children and microcephaly in adults
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mutation) contributing to approximately 1.5% of the
Finnish patients [34].
The data from the Human Gene Mutation Database
(HGMD) [35] comprise currently more than 30 different
AGU disease-causing mutations in the AGA gene. Half
of them are missense mutations. The rest of them in-
clude small deletions and insertions, splicing mutations,
gross deletions and complex rearrangements in the AGA
gene. No genotype/phenotype correlations have been de-
scribed so far.
Glycosylasparaginase and pathophysiology of
AGU
AGA encodes an L-asparaginase (glycosylasparaginase),
which catalyzes the hydrolysis of aspartylglucosamine and
other glycoasparagines with s series of larger carbohydrate
chains in lysosomes [3]. Glycosylasparaginase removes the
L-asparagine moiety from glycoasparagines and L-aspartic
acid, ammonia and free N-acetylglucosamine or a carbohy-
drate chain is generated, respectively. Both the β-amino
and β-carboxyl group of the L-asparagine moiety of the
substrates must be free in order to enable their anchorage
in the active site of glycosylasparaginase and their hydroly-
sis to occur [36, 37]. Therefore, complete proteolysis of the
polypeptide chain surrounding each L-asparagine amino
acid carrying an N-glycosidic oligosaccharide moiety must
always occur before the hydrolysis of the GlcNAc-Asn link-
age. Glycolasparaginase also acts as an L-asparaginase and
catalyzes the hydrolysis of free L-asparagine to L-aspartic
acid and ammonia [38]. Based on the mechanism of action
of glycosylasparaginase, a sensitive fluorometric to measure
its activity has been developed using L-aspartic acid β (7-
amino-4-methylcoumarin) as the substrate [39]. The com-
bined evidence indicates that glycosylasparaginase reacts
specifically toward the L-asparagine moiety of its substrates
cleaving it with a mechanism of action similar to bacterial
L-asparaginases. Thus the term “glycosylaspaganise” best
describes its mode of action.
Glycosylasparaginase belongs to a superfamily of enzymes
called as N-terminal nucleophile hydrolases [40, 41], since
it catalytically uses a processed N-terminal threonine (Thr
206) [27, 36] as both a polarizing base and nucleophile to
act on its subtrates.
The deficient activity of glycosylasparaginase activity
results in accumulation of undegraded aspartylglucosa-
mine and other glycoasparagines in body fluids and tis-
sues of AGU patients [3] and AGU mouse model [42].
Hypertrophied storage lysosomes are present in all tis-
sues and organs, but their morphology or histochemical
properties are not diagnostic to distinguish the disease
from many other lysosomal storage disorders.
Animal model
Research into the pathogenesis and therapy of AGU in
humans was hampered until an animal model for the
disease was developed through targeted disruption of
the mouse Aga gene in embryonic stem cells [42]. The
Aga-null – Aga (-/-) -mice completely lack glycosylas-
paraginase activity resulting in massive accumulation of
aspartylglucosamine in their body fluids and tissues. The
level of accumulation of GlcNAc-Asn in the Aga (-/-)
mice is very comparable to that found in urine and tis-
sues of human AGU patients.
Histopathological analyses using both light and elec-
tron microscopy demonstrated lysosomal hypertrophy in
Fig. 3 a, b Consistent dysmorphic gestalt in AGU consists of
hypertelorism, puffy eyelids, a short and broad nose with round nares
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all visceral organs resembling that of human AGU. In
the central nervous system (CNS), vacuolized neurons,
glial cells and endothelial cells were observed in all re-
gions studied including frontal cortex, cerebellum, brain
stem and spinal cord. As a conclusion, the histological
features including the distribution and appearance of the
hypertrophic lysosomes of the Aga (-/-) closely resemble
those in human AGU patients [43].
The early development of Aga (-/-) mice, like that of hu-
man AGU patients, did not show any significant pheno-
typic features. Starting at the age of 6 months, a gradual
deterioration in condition leading to impaired neuromotor
coordination, bladder function and premature death was
observed in Aga (-/-) mice [44].
Diagnosis and diagnostic methods
Vacuolated cells, as in other lysosomal storage diseases,
with expanded lysosomes can be detected in all AGU pa-
tient tissues in microscopic examinations. Biochemical
diagnosis AGU is based on the examination of urinary oli-
gosaccharides [45–47] and assay of glycosylasparaginase ac-
tivity. Demonstration of accumulated aspartylglucosamine
[48, 49] and other glycoasparagines in urine must lead to
the measurement of glycosylasparaginase activity e.g., in
serum, leukocytes or fibroblasts [50, 51]. The enzyme assay
in cultured amniotic fluid cells or chorionic villus samples
[52, 53] or directly in amniotic fluid enable prenatal detec-
tion of the disease. The analysis of amniotic fluid glycoas-
paragines may not permit reliable diagnosis of AGU [54].
Analysis of urinary aspartylglucosamine or other glycoas-
paragines, or glycosylasparaginase activity e.g., in leukocytes
[51], however, do not allow reliable carrier detection of
AGU, but DNA tests are needed for that purpose. There
are DNA tests available to detect the AGUFIN major muta-
tion [27–29] and AGUFIN minor mutation [34] and carriers
of those mutations [55, 56].
Differential diagnosis
An early growth spurt (Fig. 1) and development of macro-
cephalia (Fig. 2) followed by delayed speech development,
physical clumsiness and exceptional placidity or periods of
hyperactivity in a child with AGU-characteristic facial fea-
tures (Fig. 3) usually rises a suspicion of AGU in Finland
where the disease is well-known among child neurologists.
The early signs in other diseases manifesting as intellectual
disability included in the Finnish disease heritage, such as
Salla disease, neuronal lipofuscinoses and Northern epi-
lepsy, appear in another way. Poor eye contact, nystagmus,
and ataxia associated to general muscle hypotony are the
first signs in Salla disease; impaired vision in different types
of neuronal lipofuscinoses; and epileptic seizures in
Northern epilepsy.
The presence of vacuolated lymphocytes in peripheral
blood and dilated, large lysosomes in tissue cells of a patient
may be the first finding to indicate a lysosomal storage dis-
ease. A careful examination of the histology specimens may
indicate whether the accumulating compound might be
composed of lipids, glycosaminoglycas or oligosaccharides
suggesting the further studies to identify the storage mater-
ial. All disorders of glycoprotein degradation – including
AGU – result in accumulation of oligosaccahrides in body
fluids and tissues. Analysis of oligosaccharides in urine is
best way to screen these disorders (see earlier). The same
applies to such lysosomal storage disorders as certain types
of gangliosidoses, sialic acid storage disorders and I-cell dis-
ease. Glycosaminoglycans in urine should also be analyzed
to rule out various types of mucopolysaccharodoses. The
identification of the structure of the accumulated material
leads to specific enzyme analyses and the lack of the activity
of a particular lysosomal enzyme activity finally confirms
the correct diagnosis of the lysosomal disease. The assay of
the activity of the missing enzyme – glycosylasparaginase -
can be used to diagnose other potential AGU patients in
the family or prenatal testing. The sequence analysis of the
cDNA or gene of the affected enzyme protein often reveals
the mutation behind the structural defect in the enzyme
protein and the analysis of this mutation can be used e.g.,
to carrier detection, prenatal diagnosis or diagnosis other
affected individuals in the family.
Management and treatment
It is generally accepted that the intracellular accumu-
lation of storage material –glycoasparagines – in the
deficiency of glycosylasparaginase leads to the multi-
system AGU disease characterized by progressive
psychomotor retardation and structural changes in
various tissues. Thus it is reasonable to assume that
timely correction of the intracellular activity of glyco-
sylasparaginase would prevent of the accumulation of
glycoasparagines and thus the progression of the clin-
ical symptoms of the AGU patients would cease and
potentially reverse.
There is currently no curative treatment for human
AGU disease. Some patients in Finland and Sweden have
undergone bone marrow transplantation with no benefit
[57, 58]. Associated impairments like epileptic seizures,
psychotic periods and arthritis are treated according
general therapeutic guidelines. Carbamazepine has been
used as a drug of choice effective in the treatment of
epilepsy. The aim of rehabilitation and education is as
proficient as possible mastery of social and independent
living skills and good self-esteem. The rehabilitation plan
is build individually and most often includes training at
kindergarten and a special school for children with de-
velopmental disorders, speech and occupational therapy
during childhood. Adult AGU patients often benefit
from physio- and music therapy.
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Experimental therapy
In vitro experiments demonstrate that the metabolic de-
fect in AGU fibroblasts and lymphocytes can effectively be
corrected by enzyme replacement therapy with recombin-
ant human glycosylasparaginase [59]. Correction of intra-
cellular glycosylasparaginase activity to the level of 3–4%
of that in normal lymphocytes cleared cultured human
AGU lymphocytes from intracellular aspartylglucosamine
stores and its further accumulation was prevented. Cell-
to-cell transfer of glycosylasparaginase from normal to
AGU cells occurs [60].
Recombinant human glycosylasparaginase is biologically
active also in the experimental enzyme replacement ther-
apy of the AGU mouse model [61]. Pathophysiologic char-
acteristics of AGU were effectively corrected in non-
neuronal tissues of adult AGU mice during 2 weeks of
AGA therapy. At the same time, glycosylasparaginase ac-
tivity increased to 10% of that in normal brain tissue and
aspartylglucosamine amount was reduced by 20% in total
brain of the treated Aga (-/-) mice. AGA therapy in new-
born mice was even more effective reducing the amount
of stored aspartylglucosamine in the brain tissue up to
40%. The response to therapy was dose-dependent: the
higher the glycosylasparaginase dose the faster the clear-
ance of aspartylglucosamine [62]. Massive accumulation
of a larger glycoasparagine (Man2GlcNAc-Asn) in tissues
of AGU mice was also effectively corrected with glycosy-
lasparaginase replacement therapy [63].
Interestingly, added glycosylasparaginase can induce
apoptosis of L-asparagine-dependent leukemia cells in vivo
by depleting the cells from their L-asparagine stores [64].
Fetus and newborn
AGU has been diagnosed prenatally demonstrating the
deficiency of glycosylasparginase activity in cultured amni-
otic fluid cells [52, 53]. Electron microscopic evidence of
lysosomal storage was observed in several organs includ-
ing kidneys of the fetus affected by AGU. Elevated amount
of aspartylglucosamine in the midterm amniotic fluid
from the pregnancy with the fetus affected by AGU fur-
ther demonstrates of the presence of the metabolic defect
of AGU prior to birth. Neonatal detection of AGU can be
accomplished demonstrating lacking glycosylasparaginase
activity in umbilical cord serum samples [65].
Prognosis
Table 1 summarizes various effects of the missing activ-
ity of glycosylasparaginase on the AGU patients. An
AGU disease carrier may have a higher risk of arthritis
and their facial bones show features characteristic to
AGU disease [5, 18]. Life expectancy for Finnish female
patients is on the average 50 years and for men 45 years.
The oldest known patient lived to the age of 69 years.
Before death the patients usually experience a period of
inactivity, poor general condition and fatigue. A dystonic
status refractory to treatment may last for several days
just before death. Autopsy findings if Finnish AGU
patients suggest that the patients usually die of severe
bacterial infections, mostly pulmonary infections.
Future aspects
Treatment of various lysosomal diseases has made a
marked progress during the past two decades. The de-
velopment of a variety of innovative therapeutic ap-
proaches include increasing the residual activity of the
missing enzyme by stem cell transplantation, pharmaco-
logical chaperons, combination of chaperons and en-
zyme replacement therapy, substrate reduction therapy
and gene therapy (for references [66]). Experience from
these therapies will be beneficial in tackling the main
limitations associated to enzyme replacement therapy in
lysosomal diseases such as high cost, immunologic re-
sponse and lack of efficacy to central nervous system.
They represent significant challenges for future develop-
ment of new drugs for treatment of AGU as well.
Conclusions
AGU studies have been conducted in many countries and
new patients representing non-Finnish AGU mutations are
frequently found. Although there is no curative treatment
for this progressive disease it is considered important to
share the information of its clinical course. The patients
and their families can be supported in many ways, i.e., by
providing both medical, educational and social services dur-
ing the patient’s life span. Most health issues associated
with AGU, e.g., like epilepsy, rheumatoid arthritis, and in-
fections, can be treated according to general guidelines. On
the other hand, it may help families to overcome the diffi-
cult phases of disease’s course to know that the stressful,
drug-refractory manic-apathetic periods, which are known
Fig. 4 Piezogymic papules in heel in a patient with AGU
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to affect about 20% of patients during their adolescent
years, usually subside in young adulthood. Also, physiother-
apy and other therapies thorough life can often be benefi-
cial. The great importance of peer support of the family
association should not be forgotten either. From the socio-
educational perspective the burden of parents can be eased
by individually tailored learning goals in early childhood
and in adolescence by organizing suitable daily activities in
group homes and/or day care centers. Later on most of the
diseased persons need a nursing home. Once the special
needs of the patients are met and treated, they themselves
are usually quite satisfied with their daily living. Successful
therapy of AGU will require therapeutic strategies, which
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MRI: Magnetic resonance image
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